We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Serum Test for Ovarian Cancer Helps Determine Type of Required Surgery

By LabMedica International staff writers
Posted on 17 Sep 2009
Ovarian cancer can be detected in a pelvic mass that is already known to require surgery, helping patients and health care professionals decide what type of surgery should be done and by whom.

Called OVA1, the qualitative serum test for ovarian cancer combines the results of five immunoassays into a single numerical score. More...
The test is indicated for women who meet the following criteria: the patient is over age 18, an ovarian adnexal mass is present for which surgery is planned, and the patient has not yet been referred to an oncologist.

The immunoassay identifies five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II). An algorithm is then used to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

OVA1test was developed by Vermillion, Inc. (Freemont, CA, USA) a molecular diagnostics company, in cooperation with Quest Diagnostics (Madison, NJ, USA), a provider of cancer diagnostics. Quest Diagnostics has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years. The U.S. Food and Drug Administration (FDA) has cleared the OVA1 test, as an indication of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even when radiological test results fail to indicate malignancy.

The test should not be used without an independent clinical/radiological evaluation. It is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Vermillion, Inc. is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. Vermillion has diagnostic programs in oncology, hematology, cardiology, and women's health.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.

Related Links:
Vermillion, Inc.
Quest Diagnostics


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.